Genmab — November 2017
-
Ja det er indregnet, men burde alligevel skabe en positiv stemning.
-
P/E er nede omkring 50 efterhånden og det er attraktivt, når man ser på den eksplosive vækst selskabet står overfor i fremtiden.
-
-
Tysk rival giver Genmab modstand i amerikansk patentsplid
Selvom EU's patentdomstol har tilbagekaldt et af Morphosys' patenter, har retstvisten mellem Genmab og den tyske rival taget en drejning til fordel for Morphosys i USA.
Finans (finans.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
